Chemical Business Newsbase articles from March 2010, page 8

Chemical Business Newsbase archives from March 2010

Explorers fail to strike oil in test sites off Falklands: Desire Petroleum's shares slump after disappointing results from drilling tests.
March 30, 2010... Fears about the lack of significant oil finds to the north of the Falkland Islands escalated after two companies came up almost empty-handed in the first attempt for 12 years to drill in the politically sensitive region. Desire Petroleum's...

China's gold rush 'will be stampede by 2020'.
March 30, 2010... Chinese gold consumption will double over the next decade and rising demand could exhaust the nation's gold mining reserves by 2016, according to a report from the World Gold Council (WGC). In 2010 China's gold consumption was worth more than...

Polyvinyl alcohol from Taiwan; determination.
March 30, 2010... The US International Trade Commission determines, pursuant to section 733(a) of the Tariff Act of 1930 (19 USC 1673b(a)), that there is a reasonable indication that an industry in the USA is materially injured by reason of imports from Taiwan of...

Certain purified carboxymethylcellulose from the Netherlands: extension of time limit for preliminary results of antidumping duty administrative review.
March 30, 2010... The US Department of Commerce is extending the time limit for the preliminary results of the administrative review of the antidumping duty order on purified carboxymethylcellulose (CMC) from the Netherlands. The period of review is 1 Jul 2008...

Lafarge cannot mine in Meghalaya forests.
March 30, 2010... The Supreme Court on 29 Mar 2010, refused the permission for Lafarge to carry out limestone mining in Meghalaya forests. Unless the EIA clearance in accordance with Central Empowered Committee's new guidelines are obtained, the court denies...

Karnataka clears Rup 94,000 crore worth investment proposals: Projects include power, cement, steel plants, SEZ, engineering units.
March 30, 2010... The Karnataka Governments has cleared investment proposals totalling about Rup 94,000 crores. Among the proposals cleared, four are for cement projects and one for rubber products. (1 crore=10 M, 1 lakh=100,000).

Sakthi Sugars: Results for 2009.
March 30, 2010... Sakthi Sugars Ltd has posted a net profit of Rup 10,348.64 lakhs on net sales/income from operations of Rup 137,471.22 lakhs, on a stand alone basis, for the year ended Dec 2009 (net loss of Rup 7955.08 lakhs on net sales/income from operations...

BASF takes Ciba staff, R&D facility into its fold: Rationalisation process could go on for a year.
March 30, 2010... Chemicals major BASF has taken into its fold Ciba India Ltd's staff of 350, a research lab at Chandivali in Mumbai and a plant at Ankleshwar in Gujarat, through merger of Ciba India with itself. Globally, BASF acquired Ciba for over $5 bn in...

Four Rivers BioEnergy signs biodiesel sales agreement with BP Oil International Ltd.
March 29, 2010... Four Rivers BioEnergy Inc (Four Rivers) announced that its UK subsidiary, Four Rivers BioFuels Limited has secured an agreement with BP Oil International Limited, a wholly owned subsidiary of BP plc (BP) for the sale of a minimum of 60,000...

Modern Plastics announces full line of food and beverage plastic materials.
March 29, 2010... Modern Plastics offers a complete line of plastic product materials for the food and beverage industry. These products are FDA Approved and meet other food and beverage callout standards. Tecaform AH ID - this new metal detecting acetal plastic...

SunPower finalizes acquisition of SunRay.
March 29, 2010... SunPower Corp has completed its acquisition of SunRay Renewable Energy, a leading European solar power plant developer with offices in Europe and the Middle East. As a result, SunPower has expanded its project pipeline to include more than 1,200...

Sanofi-aventis: Multaq receives positive recommendation by NICE in new appraisal consultation document.
March 29, 2010... Sanofi-aventis announced that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq (dronedarone) indicating its intention to recommend...

GenVec Discontinues Phase III clinical trial of TNFerade.
March 29, 2010... GenVec Inc is discontinuing its Phase III clinical trial of TNFerade in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death...

Enobia Presents results from Hypophosphatasia impact patient survey; Enrolment complete in third clinical trial of ENB-0040.
March 29, 2010... Enobia Pharma Inc (Enobia) unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical...

Cephalon receives complete response letter for Nuvigil for the treatment of excessive sleepiness associated with jet lag disorder.
March 29, 2010... Cephalon, Inc has received a Complete Response letter from the US Food and Drug Administration (FDA) for its supplemental new drug application for Nuvigil (armodafinil) tablets [C-IV] in the treatment of patients with excessive sleepiness...

Astellas signs confidentiality agreement with OSI.
March 29, 2010... Astellas Pharma Inc confirmed today that it has entered into a confidentiality agreement with OSI Pharmaceuticals, Inc (OSIP). Under the agreement, OSI will provide Astellas with access to certain non-public information. This follows Astellas'...

Diatherix Laboratories introduces gastrointestinal test panel.
March 29, 2010... Diatherix Laboratories adds a gastrointestinal (GI) panel to its lineup of highly sensitive, rapid response diagnostic tests. In a single result, the Diatherix GI panel can detect and differentiate nine types of GI infections so physicians can...

Bacterin International obtains ISO certification.
March 29, 2010... Bacterin International Inc (Bacterin), a medical device and biologics manufacturing company, announced that it has received certification from the International Organization for Standardization (ISO) for fulfilling the requirements of ISO...

Siemens awarded three year contract with premier for diagnostic systems and tests.
March 29, 2010... Siemens Healthcare Diagnostics announces a new three-year contract with Premier Purchasing Partners LP, the group purchasing unit of Premier Inc, that includes Siemens powerful integrated diagnostic systems, several speciality diagnostic...

NexBio publishes pre-clinical study showing Das181 (fludase) anti-influenza therapy protects against secondary bacterial pneumonia.
March 29, 2010... NexBio Inc announced the publication in the Journal of Infectious Diseases of a pre-clinical study suggesting that treatment with Das181 (Fludase) may reduce the risk of secondary bacterial pneumonia following influenza virus infection. Das181...

Sinovac enters exclusive supply and distribution agreements with Parenteral Biotech Ltd for India.
March 29, 2010... Sinovac Biotech Ltd (Sinovac) has entered into exclusive licence, supply and distribution agreements with Parenteral Biotech Ltd, a subsidiary of Parenteral Drugs (India) Ltd, an India-based pharmaceutical company. Pursuant to the agreements,...

Pearl Therapeutics announces positive results from Phase I trial of PT003, a bronchodilator combination therapeutic for chronic obstructive pulmonary disease, and initiation of Phase IIb trial.
March 29, 2010... Pearl Therapeutics Inc, announced positive results from a Phase I safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and...

NOVAVAX releases final results from its trivalent seasonal Influenza Vaccine Phase II Clinical Study in healthy adults.
March 29, 2010... Novavax Inc, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age...

Rigel announces expiry of waiting period under Hart-Scott-Rodino Act for licensing agreement with Astrazeneca.
March 29, 2010... Rigel Pharmaceuticals Inc, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the licence agreement between Rigel and AstraZeneca, the effectiveness of which was contingent...

Sigma Life Science adds 2,200 New Prestige Antibodies powered by Atlas Antibodies AB to its portfolio.
March 29, 2010... Sigma Life Science, announced that it has added 2200 new Prestige Antibodies powered by Atlas Antibodies to its industry-leading portfolio. The development brings Sigma Life Science's total Prestige Antibody portfolio to 8,300, covering 6,900...

deCODE and Radboud Discovery in Bladder Cancer May Link Disease Risk and Somatic Mutations in Tumours.
March 29, 2010... Sequence variants associated with cancer have to date fallen into two distinct categories. Variants in the ordinary, or 'germline,' sequence of the genome that is passed between generations were linked to risk of disease, while 'somatic'...

CHMP assessment report for Ristaben (sitagliptin).
March 29, 2010... On 29 Mar 2010, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) published the assessment report for Ristaben (sitagliptin). The applicant Merck Sharp & Dohme Ltd submitted on 2 Oct 2009 an...

Daxor Corp announces year end 2009 earnings.
March 29, 2010... Daxor Corp, a medical instrumentation and biotechnology company, announced earnings for the year ended Dec 2009. The company had basic and diluted earnings/share of $1.37 and $1.36 respectively in 2009, (basic and diluted earnings/share of $3.48...

Redpoint Bio reports 4Q and 2009 results.
March 29, 2010... Redpoint Bio Corp (Redpoint) has announced financial and operational results for 4Q and year ended 31 Dec 2009. Redpoint recorded no revenue for 4Q 2009 ($1 M in 4Q 2008) the company reported revenues of $1.9 M for 2009 ($4 M in 2008). The...

Genta Inc reports 4Q and 2009 year-end financial results.
March 29, 2010... Genta Inc reported results for 4Q and year ended Dec 2009. The company also provided an overview of recent corporate highlights and anticipated milestones. The net loss for 4Q 2009 was $11.7 M, or $0.06/basic and diluted share (net income of...

ARYx reports 4Q and 2009 results of operations.
March 29, 2010... ARYx Therapeutics Inc (ARYx) reported results of operations and provided an update on its products for 4Q and year ended Dec 2009. For 4Q 2009, ARYx reported a net loss of $5.8 M or $0.21/share (net loss of $13.1 M or $0.57 cts/share in 4Q...

DNA vaccine company Inovio Biomedical reports 4Q and year-ended 2009 financial results.
March 29, 2010... Inovio Biomedical Corp (Inovio) reported financial results for 4Q and year ended Dec 2009. Total revenue was $2.6 M for 4Q 2009 and $9.1 M for 2009 ($327,000 for 4Q 2008 and $2.1 M for 2008). The net loss attributable to common stockholders was...

BioFuel reports 4Q and year end 2009 results.
March 29, 2010... Biofuel Energy Corp announced its 4Q and year ended Dec 2009 results. Net income attributable to common shareholders was $6.8 M, or $0.21/diluted share, for 4Q 2009. For 2009, the net loss attributable to common shareholders was $13.6 M, or...

China GengSheng Minerals achieves steady growth and increased profitability for 4Q and 2009.
March 29, 2010... China GengSheng Minerals Inc (China GengSheng) announced results for 4Q and year ended Dec 2009. For 4Q 2009, sales revenue increased by 18% to about $15.3 M ($12.9 M for 4Q 2008). China GengSheng has four business segments: refractories,...

Human Pheromone Sciences announces 4Q and full year 2009 results.
March 29, 2010... Human Pheromone Sciences Inc announced results for 4Q and the year ended Dec 2009. For 4Q 2009, net revenue was $223,000 ($228,000 in 4Q 2008), and resulted in net loss of $29,000 or $0.01/share (net loss of $58,000 or $0.01/share in 4Q 2008)....

EntreMed reports 4Q and year-end 2009 financial results.
March 29, 2010... EntreMed Inc reported results for 4Q and twelve months ended Dec 2009. For 2009, revenues were $5.3 M ($7.5 M for 2008). For 2009, the company reported a net loss of $9.2 M or $0.11/share (net loss of $24.9 M or $0.29/share in 2008). Revenues...

China Medicine announces 4Q and full year 2009 results.
March 29, 2010... China Medicine Corp announced its 4Q and full year ended Dec 2009 results. China Medicine's total revenues decreased 16.3% to $20.4 M for 4Q 2009 as they mainly allocated resources in the acquisition of LifeTech in 4Q 2009. Product sales in 4Q...

Antisoma plc, Novartis Corp lung cancer drug fails in study.
March 29, 2010... Antisoma plc announces that the planned interim analysis of data from the ATTRACT-1 Phase III trial of ASA404 in previously untreated non-small cell lung cancer (NSCLC) has shown that continuation of the trial would be futile, as there is little...

Dragon Pharmaceutical Inc to go private for $0.82/share.
March 29, 2010... Dragon Pharmaceutical Inc (Dragon Pharma) has entered into a definitive merger agreement to be acquired by Chief Respect Ltd, a Hong Kong corporation, which is a newly created entity controlled by Dragon Pharma's Chairman and Chief Executive...

Cellceutix announces positive results with autism compound KM-391, showing significant improvements on key parameters in animal studies.
March 29, 2010... Cellceutix Corp announced positive results in an animal study of its recently acquired autism compound, KM-391. In this carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level,...

Oxygen Biotherapeutics now marketing new formulation of Dermacyte Oxygen Concentrate.
March 29, 2010... Oxygen Biotherapeutics Inc has begun distribution for its newly formulated Dermacyte Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen...

MDRNA Inc announces patent allowance covering methods for cell specific delivery of siRNAs.
March 29, 2010... MDRNA Inc announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application US 12/701,397 covering methods for the delivery of siRNAs as well as a broad array of compounds with pharmacological...

China Aoxing Pharmaceutical Corp announces company name change and a one-for-two reverse stock split.
March 29, 2010... China Aoxing Pharmaceutical Co Inc made the following announcements, effective immediately: The company changed the name of the corporation to Aoxing Pharmaceutical Co Inc, to better reflect its business and global brand extension; and the...

San Diego's Somaxon readies to wake up market for new sleeping pill.
March 29, 2010... San Diego-based Somaxon Pharmaceuticals (Somaxon) is entering a prescription sleeping pill market in which name-brand products have been steadily losing ground to the lower-cost generics preferred by managed care plans. So right out of the gate,...

YM BioSciences presents CYT387 data at International Leukaemia Conference.
March 29, 2010... YM BioSciences Inc is presenting on its JAK1/2 inhibiting small molecule at the New Directions in Leukaemia Research Conference in Queensland, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2...

JumpStart invests in and provides entrepreneurial assistance to Thermalin Diabetes Inc.
March 29, 2010... JumpStart Ventures (JumpStart), announced an investment commitment of $250,000 in Thermalin Diabetes Inc. The young biopharmaceutical company is developing new insulin treatments for patients with diabetes. Thermalin's insulin analogs, which are...

Ranbaxy Laboratories and Pfenex Inc announce collaboration for the development of a biosimilar therapeutic protein.
March 29, 2010... Ranbaxy Laboratories Ltd (Ranbaxy) and Pfenex Inc announced that Ranbaxy will develop an undisclosed biosimilar therapeutic produced in the Pfenex Expression Technology platform, a Pseudomonas-based recombinant protein expression technology....

Gentronix Ltd launches Bluescreen HC and expands services with Comet assay testing.
March 29, 2010... Gentronix has launched its innovative early genotoxicity screening assay BlueScreen HC and an in vitro Comet testing service. Introduced at the recent Society of Toxicology 49th Annual Meeting and ToxExpo in Salt Lake City, these cell-based...

Kineta Inc awarded National Institutes of Health (NIH) grant to complete pre-clinical studies on Type 1 diabetes/multiple sclerosis drug candidate.
March 29, 2010... Kineta Inc announced receipt of a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Awarded under the NIAID's expanded Phase...

Suven Life Sciences Ltd secures 8th product Patent from European Patent Office (EPO) for their NCE to treat central nervous system (CNS) disorders.
March 29, 2010... Suven Life Sciences Ltd (Suven) announces that the European Patent Office (EPO) has issued a product Patent: EP1919896 to one of their New Chemical Entity (NCE) which is for the treatment of disorders associated with Neurodegenerative diseases...

Action Pharma completes dosing in Phase II clinical trial with AP214 to prevent acute kidney injury associated with cardiac surgery.
March 29, 2010... Action Pharma A/S has completed dosing in the second Phase II clinical trial with its leading development candidate, AP214. Interim efficacy data are expected Jun 2010. AP214 is being developed for protection of acute kidney injury in patients...

Chakra Biotech Sdn Bhd completes Series B investment round.
March 29, 2010... Chakra Biotech Sdn Bhd has completed a Ringgit 18.2 M Series B funding round. This brings total funding for the company to Ringgit 20 M. Malaysian Life Sciences Capital Fund Ltd and the Malaysian Technology Development Corp Sdn Bhd participated...

Research Park biotech firm Chromatin Inc expands operations at University of Illinois.
March 29, 2010... The University of Illinois has announced that Chromatin Inc, a biotechnology company that has occupied space in the University's Research Park since 2005 as part of the EnterpriseWorks incubator, is expanding operations and graduating to a 5000...

Living Cell Technologies receives approval to progress its human Phase II trial of Diabecell treatment for diabetes to next stage with encouraging data.
March 29, 2010... Living Cell Technologies Ltd (Living Cell), a global company pioneering the development of a cell implant to treat diabetes, has announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical...

Alcon completes acquisition of Durezol and Zyclorin from Sirion.
March 29, 2010... Alcon Inc has announced that it received regulatory approval and finalized the acquisition of the rights in the US for Durezol emulsion and the global rights, excluding Latin America, for Zyclorin from Sirion Therapeutics Inc. Alcon will...

Multiple Myeloma Research Foundation grants $1 M each to Intellikine Inc and Tragara Pharmaceuticals Inc to advance next-generation therapies for multiple myeloma.
March 29, 2010... The Multiple Myeloma Research Foundation (MMRF) has announced that two San Diego area biotech firms, Intellikine and Tragara Pharmaceuticals Inc (Tragara) will receive funding via its MMRF Biotech Investment Award programme. The MMRF Biotech...

Enzo Biochem says favourable patent Appeals Court decision will allow pursuit of claim for substantial damages.
March 29, 2010... Enzo Biochem Inc (Enzo) said that a decision released on 26 Mar 2010 by the Court of Appeals for the Federal Circuit reversing a district court's summary judgement will enable the company to pursue a claim for substantial damages against Applera...

NexMed files Investigational New Drug Application with FDA for cancer drug candidate.
March 29, 2010... NexMed Inc has filed an Investigational New Drug (IND) application with the US Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco, in combination with doxorubicin in patients with...

Research and Markets: The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues.
March 29, 2010... Research and Markets has announced the addition of The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues report to their offering. The Future of Dermatology Therapeutics,...

Gemin X completes patient enrolment in Phase II clinical study of obatoclax for first-line treatment of small cell lung cancer.
March 29, 2010... Gemin X Pharmaceuticals (Gemin X) announced the completion of patient enrolment in a Phase II clinical trial of the company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The...

Hexion Specialty Chemicals Inc and Shanxi Sanwei Group Co Ltd form joint venture company, will build plant in Shanxi Province, China to produce VeoVa monomer.
March 29, 2010... Hexion Specialty Chemicals Inc (Hexion), and Shanxi Sanwei Group Co Ltd (Sanwei), announced the formation of a joint venture company that will build and operate a new plant in Shanxi Province, China, to produce VeoVa monomer, a key building...

Celerion acquires early stage clinical research operations from MDS Pharma Services.
March 29, 2010... Celerion has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical...

Ligand presents first-in-human Phase I data on lead SARM molecule LGD-4033 at the International Congress of Endocrinology.
March 29, 2010... Ligand Pharmaceuticals Inc (Ligand) announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 14th International Congress of Endocrinology in Kyoto,...

Regulus Therapeutics and collaborators publish pre-clinical in vivo efficacy data on microRNA Therapeutics targeting microRNA-10b in models of breast cancer metastasis.
March 29, 2010... Regulus Therapeutics Inc (Regulus) announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting...

Pro-Pharmaceuticals licenses to Procaps SA exclusive marketing and distribution rights to commercialize Davanat to treat cancer in Colombia, South America.
March 29, 2010... Pro-Pharmaceuticals Inc has granted Procaps SA exclusive rights to market and sell Davanat to treat cancer in Colombia, South America. Phase II clinical trial results for late-stage colorectal cancer patients demonstrate that when Davanat is...

Merck Serono: Erbitux granted extended use in Japan for 1st-Line Treatment of mCRC patients with KRAS wild-type tumours.
March 29, 2010... Merck Serono announced that Erbitux (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor (EGFR)-expressing, curatively unresectable (inoperable),...

New nuclear reactor sites.
March 29, 2010... The Union Government of India has permitted the construction of nuclear power reactors of 700 MW capacity each. The reactors will be Pressurised Heavy Water Reactors (PHWRs) that will use uranium as fuel and heavy water as both moderator and...

Congo: Glencore increases stake in Katange Mining.
March 29, 2010... Glencore International SA is to increase its stake in Katanga Mining Ltd by 5.2% to 74.4%. This will result from transactions with Breton Global Ltd and Ellesmere Global Ltd with a value of $75.6 M, or 100 M shares. Katanga operates an extensive...

Iran: Lukoil withdraws from oil production.
March 29, 2010... Lukoil is to give up its production project in Iran because of possible US sanctions. Experts say there is also a political motive behind the withdrawal. Lukoil had signed a deal in 2003 for exploration work at the Anaran oil deposits. Its stake...

Growing demand for building chemicals and computers in Gulf States.
March 29, 2010... Demand for building chemicals in the Gulf Cooperation Council (GCC) will grow at 4.2%/y from 2009 to 2015, to reach $1.2 bn, according to Frost & Sullivan. The future of the GCC market in building chemicals will be dependent on two sectors:...

Egypt: cement industry expanding capacity.
March 29, 2010... Egypt's cement industry is profiting from a growing building sector. There was double-digit growth in 2009. Export bans and price controls have been unable to conceal the threat of capacity becoming tight in future. The government thus plans to...

China: higher zinc consumption expected.
March 29, 2010... China's zinc demand is expected to rise to 5.4 M tonnes in 2010, from 5 M tonnes in 2009. Production is expected to be up from 4.4 M tonnes to 5.18 M tonnes, following expansion of domestic smelters. Imports will fall, however, from 670,000...

Canada: oil sands investment falling on fruitful ground.
March 29, 2010... Investors in Canada's oil sands industry are gradually revisiting postponed, billion-figure projects. The celebrated research institute, Conference Board of Canada, is now forecasting a rise in oil sands production in the coming years. Income...

Oil group PetroChina posts fall in profits in 2009.
March 29, 2010... China's PetroChina posted a fall in profits in 2009 because of lower oil prices. 2010 profits could benefit from rising output and higher energy prices. Crude oil production should rise 1.2% in 2010 to 853.7 M barrels, following a 3.1% fall in...

Russia: Yokohama Rubber investing EUR 293 M in tyre plant.
March 29, 2010... Japanese tyre producer Yokohama is to Roubles 11.7 bn (EUR 293 M) in a plant in Lipezk, southwest of Moscow. The new plant will trade as Yokohama RPZ LLC. Production will begin in 2011 and reach full capacity of initially 1.4 M car tyres in...

Arkema announces the sale of its Higher Methacrylates business.
March 29, 2010... In the scope of the restructuring of its methacrylics activity, Arkema has reached an agreement with Evonik for the sale of its Higher Methacrylates business. This Higher Methacrylates business concerns n-butyl methacrylate, i-butyl...

AGC to establish BUPT-AGC Ultra-High Speed Fluororesin-Based Plastic Optical Fiber Technological Combined Laboratory, jointly with the Beijing University of Posts and Telecommunications; Aiming to make Fontex, a commercial plastic optical fiber enabling w.
March 29, 2010... AGC (Asahi Glass Co Ltd) has decided to establish the BUPT-AGC Ultra-High Speed Fluororesin-Based Plastic Optical Fiber Technological Combined Laboratory, which will conduct applied research on the company's Fontex, a plastic optical fiber...

Astellas signs confidentiality agreement with OSI.
March 29, 2010... On 29 Mar 2010, Astellas Pharma Inc announced that it has signed a confidentiality agreement with OSI Pharmaceuticals Inc that will provide Astellas with non-public information pursuant to Astellas' tender offer for OSI's shares. There is...

Chemtura announces price increase on bromine-based products.
March 29, 2010... On 29 Mar 2010, Chemtura Corp, debtor-in-possession, announced that it will increase prices in all regions on bromine-based products by up to 25%, where contracts allow. Anne Noonan, vice president of Flame Retardants, Brominated Performance...

Eastman 168 non-phthalate plasticizer achieves US and EU approval.
March 29, 2010... On 29 Mar 2010, Eastman Chemical Co announced that in addition to the existing Food Contact Notification (FCN) clearance from the US Food and Drug Administration (FDA), its Eastman 168 non-phthalate plasticizer is now listed in EU Commission...

Cognis at Vitafoods 2010: an oasis of wellness.
March 29, 2010... At this year's Vitafoods trade show, to be held on 18 to 20 May in Geneva, Switzerland, Cognis Nutrition & Health will be exhibiting at stand 741 a variety of new products and beauty concepts that serve the latest market trends. Following...

Hexion Specialty Chemicals Inc and Shanxi Sanwei Group Co Ltd form joint venture company, will build plant in Shanxi Province, China to produce VeoVa monomer.
March 29, 2010... On 29 Mar 2010, Hexion Specialty Chemical Inc and Shanxi Sanwei Group Co Ltd, announced the formation of a joint venture company that will build and operate a new plant in Shanxi Province, China, to produce VeoVa monomer, a key building block...

Linde's electronics and specialty gases business in North America completes integration of Spectra Gases.
March 29, 2010... The integration of Spectra Gases into Linde North America is now complete and customers throughout the world will benefit from the synergy it has created. Linde North America is a member of The Linde Group, a leading global gases and engineering...

Pharma and biotech firms improve quality and productivity with Linde technology.
March 29, 2010... Pharmaceutical manufacturers and biotech firms looking to make increasingly advanced, higher quality products now have a supplier who can design and deliver cost-effective solutions to address their most stringent operational and environmental...